Acyclovir

C. diff Risk

None

Oral Bioavailability

NA

Approximate Cost

Spectrum Of Activity

Dosing

10 mg/kg IV q8h (Dose by adjusted body weight if BMI 30 or greater)

HSV: 400 mg PO TID

VZV: 800 mg PO 5 times per day

General Information

Adverse Effects

GI upset, phlebitis- common

Increased SCr, AKI from crystal nephropathy

Major Interactions

Mycophenolate can increase the acyclovir concentration

May diminish efficacy of zoster or varicella vaccine

Pharmacology

Antimicrobial class: Antiviral, nucleoside analogue

Pregnancy category: B